Researchers at Johns Hopkins University and the University of Maryland School of Pharmacy have developed a set of novel, first-in-class drugs that inhibit hypoxia-inducible factors 1 and 2, a pair of transcription factors considered to be “master regulators” of cancer progression. The study, to be published April 2 in the Journal of Experimental Medicine (JEM), shows that these drugs, when combined with immunotherapy, can completely eliminate breast, colorectal, melanoma, and prostate tumors in mice, suggesting that they could eventually be used to treat a broad range of cancers in humans.

The National Comprehensive Cancer Network and NCCN Foundation select five Young Investigator Award recipients from Fred Hutchinson Cancer Center, Memorial Sloan Kettering Cancer Center, O'Neal Comprehensive Cancer Center at UAB, Siteman Cancer Center at Barnes-Jewish Hospital and WashU Medicine, and The University of Texas MD Anderson Cancer Center.

Children with the rare but serious allergic disease FPIES have an atypical gut microbiota compared to healthy children. This is shown in a new study from Umeå University, published in the scientific journal the Journal of Allergy and Clinical Immunology.

Sepsis and septic shock are the leading causes of death in intensive care units worldwide.  Controlling the dysregulated host response that drives inflammation, hemodynamic collapse, and multiple organ failure is challenging. In a comprehensive narrative review, Italian and French researchers examine the clinical applications of the oXiris® membrane, an advanced extracorporeal blood purification filter designed to combine continuous renal replacement therapy (CRRT) with targeted removal of inflammatory mediators and bacterial endotoxins in critically ill patients.